Sign in
Taking people in Hong KongNo phase

Tracks survival of adults with unresectable liver cancer in routine care

Observes how long adults with inoperable liver cancer survive under usual treatment in Asia Pacific.

Key facts

Who runs it
Humanity & Health Medical Group Limited
Where
Hong Kong, Hong KongSee the siteAlso in 2 other countries, 2 sites
Trial code
Registry title
The Overall Survival of Patients With Unresectable HCC in Real-life
Status
Recruiting
People taking part
5,000 people, planned
Started
16 Jul 2018
Planned end
31 Dec 2025
Type of study
Observational
Record updated
24 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults diagnosed with hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery. It follows how long they live in routine care.

Age
18 years or older
Sex
All sexes can join
Disease stage
Hepatocellular carcinoma that cannot be removed by surgery (unresectable)

Main reasons for not taking part

  • Not willing to take part
  • Not willing to give written informed consent

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Patients with a diagnosis of unresectable hepatocellular carcinoma
  • Able to comprehend and provide written informed consent in accordance with institutional guidelines

Who cannot take part

  • Patients not willing to participate and/or give their written informed consent

Where in Hong Kong

Also in 2 other countries, 2 sites

  • Humanity & Health Medical Group LimitedHong Kong, Hong KongContact: George Lau, MDTaking people

About the trial

What the trial wants to find out

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China).

Read full original descriptionShow less

The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Overall Survival of Patients Diagnosed With Unresectable Hepatocellular Carcinoma Under Real-life Clinical Practice in Asia Pacific Region
Plain-language title
Tracks survival of adults with unresectable liver cancer in routine careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
24 March 2025